DELTA-FLY PHARMA, INC.

Delta-Fly Pharma reports smooth enrollment in Phase I/II study of DFP-10917 + Venetoclax in AML patients, with promising safety and efficacy in initial patients. Aiming for NDA approval as a safer alternative to standard Azacitidine + Venetoclax therapy, with a planned Phase III study for relapsed/refractory AML patients.